Effects of a single arthrocentesis and a COX-2 inhibitor on disorders of temporomandibular joints. A preliminary clinical study.
Our aim was to examine the short-term effect of combined treatment with single arthrocentesis and a COX-2 inhibitor on 26 patients with severe symptoms of temporomandibular joint (TMJ) disorders. The severity of the disorders was graded according to the degree of restriction of mouth opening and pain score on a visual analogue scale. Synovial fluid was collected from the superior joint space of the affected TMJ, and arthrocentesis was done with isotonic saline, 200ml. Subsequently, etodolac, 400mg/day, was given for 2 weeks. At 14 days, patients were re-examined and further specimens of synovial fluid were collected. Patients generally lost their symptoms and the severity of the disorders improved significantly (P<0.01). The concentrations of total protein and albumin in synovial fluid decreased with no statistical significance. However, the concentration of matrix metalloproteinase-3 and its ratios to total protein and albumin did decrease significantly (P<0.05). Our results suggest that a larger controlled study is necessary to clarify the contributory effect of arthrocentesis and etodolac for patients with severe symptoms of TMJ disorders.
Ishimaru
J-I
JI
Department of Oral and Maxillofacial Surgery, Gifu Prefectural Gifu Hospital, Gifu, Japan. ishmaru@ktroad.ne.jp
Ogi
N
N
Mizui
T
T
Miyamoto
K
K
Shibata
T
T
Kurita
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000418:Albumins / Q000032:analysis; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D017308:Etodolac / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000032:analysis; D008565:Membrane Proteins; D008875:Middle Aged; D010147:Pain Measurement; D019152:Paracentesis / Q000379:methods; D010544:Peroxidases / Q000037:antagonists & inhibitors*; D011451:Prostaglandin-Endoperoxide Synthases; D011506:Proteins / Q000032:analysis; D018709:Statistics, Nonparametric; D013582:Synovial Fluid / Q000737:chemistry; D013705:Temporomandibular Joint Disorders / Q000145:classification / Q000628:therapy*
D000418:Albumins; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011506:Proteins; D017308:Etodolac; D010544:Peroxidases; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D019278:Matrix Metalloproteinase 3